Fig. 7: A2-APM treatment induces prolonged immune memory and protects the GBM mice against rechallenge with tumor cells.

a Description of the in vivo study plan. On days 7 and 14 after GL261 cell transplantation, mice received different treatments via i.v. injection. Then 3 out of the survived mice on day 45 post-inoculation were selected for the analysis of effector memory T cells in splenocytes. b Representative flow cytometry dot plot of CD8⁺CD44^hi memory T cells in brain and draining lymph nodes (dLNs) of naïve and A2-APM treated mice. c Representative flow cytometry histogram and quantification of CD62L^hi memory T cells in the brains of naïve and A2-APM treated mice (n = 3). d Representative flow cytometry dot plot of CD44^hi CD62L^hi central memory T cells (T_CM) and effector memory T cells (T_EM) in spleen of naïve and A2-APM treated mice. e Quantification of CD44^hiCD8⁺ memory T cells in the brain and dLNs, CD44^hi CD62L^hi central memory T cells (T_CM) and effector memory T cells (T_EM) in the spleen of naïve and A2-APM treated mice (n = 3). f 3 out of the survived mice on day 45 post-inoculation were rechallenged with GL261 tumor cells to check the performance of long-term memory effect. MR images of naïve and A2-APM treated mice rechallenged with GL261 cells on days 45 and 59. The yellow dashed lines indicate the tumor area. g Survival curves for naïve (n = 4) and A2-APM (n = 3) treated mice after rechallenging with GL261 cells. All statistics are expressed as mean ± SD. Statistical significance was calculated by two-sided t-test in (c) and (e). Statistical significance was calculated by log-rank test in (g). Source data are provided as a Source Data file.